Researchers found no evidence to suggest that low-dose aspirin protects against cognitive decline or dementia, and neither did they find any evidence for improvements in cognitive test scores related to low-dose aspirin. These results come from a systemic review and meta-analysis of observational and interventional studies in older individuals, published in the Journal of the American Geriatrics Society.
Eight studies were included in the analysis, which included a total of 36,196 individuals without dementia or cognitive impairment at baseline (mean age 66, 63% female). Low-dose aspirin use was defined as (<300mg/d).
The analysis showed that over a median of 6 years, chronic use of low-dose aspirin was not associated with onset of dementia or cognitive impairment (5 studies, N=26,159; OR=0.82, 95% CI=0.55–1.22, P=0.33). Furthermore, an analysis of three randomized control trials, including 10,037 individuals with a follow-up of 5 years, showed that the use of low-dose aspirin was not linked with a significantly greater global cognition (SMD=0.005, 95% CI=–0.04–0.05, P=0.84).
It was noted that the incidence of adverse events was higher among participants taking aspirin over the controls, whilst adherence was lower in the aspirin groups than in the controls.
“Additional studies are needed to test the possibility that low-dose aspirin has beneficial effects when taken over a longer period and at an earlier age,” said Dr. Nicola Veronese, lead author of study.
For more information visit Wiley.com.